Senti Biosciences, Inc. (Nasdaq: SNTI) announced its financial results for the year ended December 31, 2025, highlighting significant progress in its clinical programs and financial position. The company reported cash and cash equivalents of approximately $16.4 million as of December 31, 2025. Research and development expenses for the year totaled $37.6 million, while general and administrative expenses were $26.2 million. The net loss for the year was $61.4 million, or $2.73 per share, which included a non-recurring impairment of long-lived assets of $5.1 million and stock-based compensation of $5.7 million. Senti Bio's lead program, SENTI-202, has shown promising clinical data in treating relapsed/refractory acute myeloid leukemia (AML), and the company received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for this treatment. CEO Timothy Lu expressed pride in the team's commitment and the progress made in 2025, positioning the company for future opportunities. The report also included a press release detailing these results and updates, which is available as Exhibit 99.1 to the Form 8-K.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.